Phosphopenic Osteomalacia with Multiple Fractures as an Adverse Effect of Long-Term Tenofovir Therapy for Hepatitis B

Abstract

This article presents a case report and a review of sources about hypophosphatemic osteomalacia, a rare adverse effect of chronic hepatitis B treatment with tenofovir disoproxil fumarate. Hypophosphatemic osteomalacia is caused by partial or complete Fanconi syndrome or reduced renal function due to acute or chronic damage to the proximal renal tubules. This case report describes manifestations such as multiple skeletal fractures, including rib and vertebral fractures, left acetabular and sacral fractures, bone and joint pain, signs of neuropathy, and severe muscle weakness. However, bone mineral density remained normal. There was also evidence of osteonecrosis of the talus, scaphoid, and medial cuneiform. Differential diagnoses included vitamin D deficiency, diabetic nephropathy and neuropathy, cancer, and hematologic disorders. The diagnosis was suspected by a decrease in blood phosphate levels and tubular reabsorption of phosphate, and by elevated levels of fibroblast growth factor 23. Discontinuation of tenofovir resulted in rapid clinical improvement and normalization of mineral metabolism, including estimated tubular phosphorus reabsorption and ratio of maximum rate of renal tubular reabsorption of phosphate to glomerular filtration rate.

Keywords

hypophosphatemia / osteomalacia / fractures / tenofovir

References

[1] Uday S, Högler W. Nutritional rickets and osteomalacia in the twenty-first century: revised concepts, public health, and prevention strategies. Curr Osteoporos Rep. 2017;15(4):293–302. doi: 10.1007/s11914-017-0383-y Erratum in: Curr Osteoporos Rep. 2017;15(5):507. doi: 10.1007/s11914-017-0395-7

[2] Megapanou E, Florentin M, Milionis H, et al. Drug-induced hypophosphatemia: current insights. Drug Saf. 2020;43(3):197–210. doi: 10.1007/s40264-019-00888-1

[3] Kuznetsov NI, Moiseeva IE. Modern principles of etiotropic therapy for chronic hepatitis B and C. Russian family doctor. 2022;26(4):7–15. EDN: TPRCSA doi: 10.17816/RFD112383

[4] Liu Z, Zhao Z, Ma X, et al. Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis. BMC Gastroenterol. 2023;23(1):384. doi: 10.1186/s12876-023-03027-4

[5] Medland NA, Chow EP, Walker RG, et al. Incidence of renal Fanconi syndrome in patients taking antiretroviral therapy including tenofovir disoproxil fumarate. Int J STD AIDS. 2018;29(3):227–236. doi: 10.1177/0956462417722133

[6] Sutton SS, Magagnoli J, Hardin JW, et al. Association of tenofovir disoproxil fumarate exposure with chronic kidney disease and osteoporotic fracture in US veterans with HIV. Curr Med Res Opin. 2020;36(10):1635–1642. doi: 10.1080/03007995.2020.1816538

[7] Dessordi R, Santana RC, Navarro AM. Influence of antiretroviral therapy on bone metabolism of patients with chronic hepatitis B: a review. Rev Soc Bras Med Trop. 2019;52:e20180441. doi: 10.1590/0037-8682-0441-2018

[8] Mateo L, Holgado S, Mariñoso ML, et al. Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients. Clin Rheumatol. 2016;35(5):1271–1279. doi: 10.1007/s10067-014-2627-x

[9] Rao M, Dadey L, Glowa T, Veldkamp P. Fanconi syndrome leading to hypophosphatemic osteomalacia related to tenofovir use. Infect Dis Rep. 2021;13(2):448–453. doi: 10.3390/idr13020044

[10] Iatan I, Lee TC, McDonald EG. Tenofovir-induced osteomalacia with hypophosphataemia. BMJ Case Rep. 2021;14(5):e240387. doi: 10.1136/bcr-2020-240387

[11] Joseph A, Cherian KE, Kapoor N, Paul TV. Tenofovir-induced hypophosphatemic osteomalacia: how do bone mineral density, trabecular bone score and proximal hip geometry change with treatment? Endocrinol Diabetes Metab Case Rep. 2023;2023(1):22–0259. doi: 10.1530/EDM-22-0259

[12] Li J, Zang X, Heng H, et al. Fanconi syndrome induced by the long-term use of tenofovir disoproxil fumarate: a case report and literature review. J Int Med Res. 2023;51(8):3000605231195469. doi: 10.1177/03000605231195469

[13] Cundy T, Que L, Hassan IM, Hughes L. Bisphosphonate-induced deterioration of osteomalacia in undiagnosed adult Fanconi syndrome. JBMR Plus. 2020;4(8):e10374. doi: 10.1002/jbm4.10374

[14] Chung TL, Chen NC, Chen CL. Severe hypophosphatemia induced by denosumab in a patient with osteomalacia and tenofovir disoproxil fumarate-related acquired Fanconi syndrome. Osteoporos Int. 2019;30(2):519–523. doi: 10.1007/s00198-018-4679-2

[15] Diallo K, Wembulua BS, Aidara M, e al. Osteonecrosis of the humeral head in a human immunodeficiency virus-infected patient under tenofovir disoproxil fumarate-emtricitabine-lopinavir/ritonavir for 10 years: a case report. J Med Case Rep. 2021;15(1):624. doi: 10.1186/s13256-021-03145-1

RIGHTS & PERMISSIONS

Eco-Vector